Learn More
We observed vertically displaced coastal and river markers after the 27 February 2010 Chilean earthquake [moment magnitude (Mw) 8.8]. Land-level changes range between 2.5 and -1 meters, evident along an approximately 500-kilometers-long segment identified here as the maximum length of coseismic rupture. A hinge line located 120 kilometers from the trench(More)
The 2015 M w 8.3 Illapel, Chile earthquake is the latest megathrust event on the central segment of that subduction zone. It generated strong ground motions and a large (up to 11 m runup) tsunami which prompted the evacuation of more than 1 million people in the first hours following the event. Observations during recent earthquakes suggest that these(More)
There are few examples of successful CNS diagnostics owing to our poor understanding of the mechanisms of disease. This article will discuss this and other challenges facing CNS diagnostic development with a focus on Alzheimer's disease, along with a discussion of potential future diagnostic assays that may help in the development of new CNS medications.
Molecular biomarkers for antipsychotic treatments have been conceptually linked to the measurements of dopamine functions, mostly D(2) receptor occupancy, either by imaging using selective PET/SPECT radioactive tracers or by assessing plasma prolactin levels. A quest for novel biomarkers was recently proposed by various academic, health service, and(More)
This work presents the results of a regional-scale estimation of low-enthalpy geothermal resources for district heating in the Santiago basin. The purpose of this work is to identify promising areas for the development of this type of renewable energy. The estimation was based on comparison of soil thermal properties and hydrogeological parameters, using(More)
Capsaicin-induced dermal blood flow (CIDBF) is a validated biomarker used to evaluate the target engagement of potential calcitonin gene-related peptide-blocking therapeutics for migraine. To characterize the pharmacokinetics (PK) and quantify the inhibitory effects of erenumab (AMG 334) on CIDBF, CIDBF data were pooled from a single- and a multiple-dose(More)
Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) signaling are being explored as prophylactic treatments for migraine. Erenumab (AMG 334) is the first potent, selective, and competitive human mAb antagonist of the CGRP receptor. We report the data from two phase 1 studies assessing the safety, pharmacokinetics (PK), and(More)
  • 1